bluebird bio, Inc. (BLUE) Social Stream
Featured Post From StockTwits About BLUE
$BLUE SVB Leerink has a “Outperform” rating and a $72.00 price objective on the stock. SVB Leerink also issued estimates for bluebird bio’s Q4 2021 earnings at ($2.65) EPS.JJinv, published April 29, 2021
What Else are BLUE Traders Talking About?
Other tickers frequently mentioned alongside BLUE is CLVS.
Other Notable StockTweets About BLUE
$BLUE $CLVS senecabio.com/seneca-biopha...
I ain’t no pumper, but a few friends on this board just jumped on SNCA. Vote tomorrow at 11 am for R/S merger split with LBS. They approved 5/6, on April 9th. R/S left which they say they have the approval. 1.60 range now. Offering CVR, if you hold till merger takes place. Atrium out of NY throwing in 22 million & have clause they can’t short more than 20%. Institutions will jump in after merger. LBS has a few accelerated FDA approvals in place. Read up.
Just a heads up. Bullish
$BLUE this freakin pos it goes only in one direction, down! Thanks to the guy who seems confused about the company he is supposedly leading “You don’t build an oncology company by hiring people who are experts in severe genetic disease, nor do you do vice versa,” you idiot, you hire what your company needs, have you looked at the company’s pipeline lately? Sell the company or step aside before you erode whatever left of this company!z_guy, published April 16, 2021
all that buying and the price tanking, shorts having fun again.
Their will be a day (trial gets back on track) that shorts could have trouble.
$BLUE Even if they lift the hold. I'm not sure it would have much impact on the share price. IMO The rich are pulling their money out of the markets. Biden tax plans and an overvalued market have put an end to the massive investing we've seen for the last 4 years. This will probably be a great long term hold thoughMoney1738, published April 1, 2021